Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

被引：38
|
作者：
Isakoff, Steven J. [1 ]
Baselga, Jose [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; PERTUZUMAB; LAPATINIB; EFFICACY; THERAPY; COMPLEX;
D O I：
10.1200/JCO.2010.31.6679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [21] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Kemp, Zoe
    Jones, Alison
    ADVANCES IN THERAPY, 2011, 28 (08) : 603 - 614
  • [22] Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (06) : 1268 - 1274
  • [23] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Zoe Kemp
    Alison Jones
    Advances in Therapy, 2011, 28 : 603 - 614
  • [24] New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023
    Banys-Paluchowski, Maggie
    Krawczyk, Natalia
    Stickeler, Elmar
    Mueller, Volkmar
    Fehm, Tanja
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) : 54 - 61
  • [25] Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
    Chung, Clement
    Lam, Masha S. H.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (18) : 1579 - 1587
  • [26] Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reply
    Gebski, Val
    Huttunen, Teppo
    Joensuu, Heikki
    JAMA ONCOLOGY, 2019, 5 (01) : 118 - 118
  • [27] Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Xie, Jindong
    Zou, Yutian
    Gao, Ting
    Xie, Liming
    Tan, Duxun
    Xie, Xiaoming
    CANCER CONTROL, 2022, 29
  • [28] Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
    Ohzawa, Hideyuki
    Sakatani, Takashi
    Niki, Toshiro
    Yasuda, Yoshikazu
    Hozumi, Yasuo
    BREAST CANCER, 2014, 21 (05) : 563 - 570
  • [29] Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
    Hideyuki Ohzawa
    Takashi Sakatani
    Toshiro Niki
    Yoshikazu Yasuda
    Yasuo Hozumi
    Breast Cancer, 2014, 21 : 563 - 570
  • [30] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome
    Krell, Jonathan
    James, Colin R.
    Shah, Deep
    Gojis, Ondrej
    Lim, Adrian
    Riddle, Pippa
    Ahmad, Riz
    Makris, Andreas
    Cowdray, Andrew
    Chow, Angela
    Babayev, Tamerlan
    Madden, Peter
    Leonard, Robert
    Cleator, Susan
    Palmieri, Carlo
    CLINICAL BREAST CANCER, 2011, 11 (03) : 153 - 160
12345